Latest Industry Insights

Technology Networks spoke to Conor McKechnie, to learn more about the Biopharma Resilience Index and the changes required to get new therapeutics to market quicker.

Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.

This article discusses one of the key areas where innovation is needed: downstream processing.

Technology Networks recently spoke to Drew Buskirk to learn more about peak variation and why it is so important to measure.

Chris Sigley highlights some of the main findings from the Ethical Medicines Industry Group and Arkivum’s annual survey tracking the progress of digital transformation and clinical data strategies of 305 global life sciences organizations.

In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.